Wednesday, August 10, 2022 | Back issues
Courthouse News Service Courthouse News Service

Pharma Derivative

SAN JOSE - While underplaying serious side-effects of its major trial drug, Omontys (peginesatide), directors of Affymax dumped $12 million of their shares before the price sank by 84 percent, knocking $524 million off its market cap, shareholders say in a derivative complaint in Santa Clara County Court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.